Feature ‘It has just grown and multiplied … now the service could not run without our prescribing’ Owain Brooks, deputy regional lead renal pharmacist, Morriston Hospital, Swansea…Published: 6 October 2022
News Pharmacist review required in majority of acute kidney injury cases, finds pilot The pharmacy team at Wrexham Maelor Hospital in north Wales were awarded the 'Digital Impact Award' at the MediWales Innovation Awards 2021 for their software project.…Published: 24 January 2022
Opinion Top five infographics of 2020I’m sure it will come as no surprise that The Pharmaceutical Journal’s most-read infographics this year take a look at COVID-19.…Published: 22 December 2020
News ‘I have developed good working relationships with my patients beyond their diagnosis’ – a day in the life of a renal pharmacist With the support of his manager and the renal department, Aaron Acquaye is constantly striving to develop his clinical knowledge and skills. …Published: 19 October 2020
News EMA to investigate possible link between remdesivir and acute kidney injury The European Medicines Agency’s safety committee is to review reports of acute kidney injury in some patients being given remdesivir for COVID-19.…Published: 5 October 2020
Infographic Spotting the signs of acute kidney injury With 65% of cases beginning in the community, pharmacists can help detect acute kidney injury early and review patients’ medicines before their condition worsens. …Published: 23 April 2020
Opinion How my part-time medicines safety PhD changed prescribing practice for older people Pharmacist Su Wood’s work on estimating reduced kidney function led to a major change in national recommendations for prescribing in older people.…Published: 31 January 2020
Opinion At last, a new treatment option for diabetes-related chronic kidney disease Guideline-changing trial results released earlier in 2019 suggest that SGLT2 inhibitors could be a viable treatment solution for patients with diabetes and evidence of kidney damage.…Published: 20 September 2019
News SGLT2 inhibitor lowers risk of kidney failure in type 2 diabetes Patients with type 2 diabetes mellitus and chronic kidney disease have a lower risk of kidney failure and cardiovascular events if they are treated with canagliflozin, research has confirmed.…Published: 11 July 2019
News Increased intensity plus adherence maximises statin benefits High adherence to intensive lipid-lowering therapy provides the greatest risk reduction for cardiovascular events, a study in JAMA Network Open has shown.…Published: 16 January 2019
